Clinical Trials/NCT00786110

NCT00786110UnknownPhase 2

Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy

University of Turin, Italy5 sites in 1 country30 target enrollmentStarted: April 2008Last updated: February 24, 2009

Conditions

Interventions

Drugs

Trial Snapshot

Phase: Phase 2
Sponsor
Enrollment: 30
Locations: 5
Primary Endpoint: Disease free survival

Study Overview Study Design Eligibility Criteria Arms & Interventions Outcomes Investigators Sites Records & Identifiers Similar Trials

Study Overview

Brief Summary

The study is designed as a Phase II, prospective, non randomized, open-label, single arm, multicenter trial, in which patients with locally advanced or metastatic ACC not amenable to complete surgical resection and progressing to cytotoxic chemotherapy will receive Sorafenib plus metronomic chemotherapy as treatment.The aim of this phase II trial is to evaluate the clinical benefit and toxicity of the combination of Sorafenib plus metronomic chemotherapy in patients with locally advanced or metastatic ACC who progressed after first or second line chemotherapy.

Detailed Description

STUDY OBJECTIVES

The aim of this phase II trial is to evaluate the clinical benefit and toxicity of the combination of Sorafenib plus metronomic chemotherapy in patients with locally advanced or metastatic ACC who progressed after first or second line chemotherapy.

Primary objective

To assess the clinical benefit as measured by a non progressing rate after 4 months of the combination of Sorafenib plus weekly Paclitaxel in patients with locally advanced or metastatic ACC who progressed after first or second line chemotherapy.

Study Design

Study Type: Interventional
Allocation: Non Randomized
Intervention Model: Single Group
Primary Purpose: Treatment
Masking: None

Eligibility Criteria

Ages: 18 Years to 70 Years (Adult, Older Adult)
Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

•Histologically confirmed diagnosis of ACC
•Locally advanced or metastatic disease not amenable to radical surgery resection
•Radiologically monitorable disease
•Progressing disease after one or two cytotoxic chemotherapy regimens (including a platin-based protocol)
•ECOG performance status 0-2
•Life expectancy ≥ 3 months
•Subjects with at least one uni-dimensional(for RECIST) or bi-dimensional(for WHO) measurable lesion. Lesions must be measured by CT-scan or MRI
•Age ≥ 18 years
•Adequate bone marrow reserve (neutrophils ≥ 1500/mm³ and platelets ≥ 80.000/mm³)
•Hemoglobin > 9.0 g/dl
•Total bilirubin < 1.5 times the upper limit of normal
•PT-INR/PTT < 1.5 x upper limit of normal [Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.]
•Serum creatinine < 1.5 x upper limit of normal
•Effective contraception in pre-menopausal female and male patients
•Patient´s written informed consent
•Ability to comply with the protocol procedures
•Exclusion criteria:
•History of prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, or other treated malignancies with no evidence of disease for at least three years.
•History of HIV infection or chronic hepatitis B or C (This criteria should be modified to allow Hepatitis B or C in protocols looking at HCC patient population)
•Active clinically serious infections (> grade 2 NCI-CTC version 3.0)
•Symptomatic metastatic brain or meningeal tumors (unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry)
•Patients with seizure disorder requiring medication (such as steroids or anti-epileptics)
•History of organ allograft The organ allograft may be allowed as protocol specific
•Severe renal (serum creatinine > 2.5 x ULN) or hepatic insufficiency (ALT / - AST > 2.5 x ULN or ALT/AST >5 x ULN if liver function abnormalities are due to the underlying malignancy and/or total serum bilirubin > 2.5 x ULN)
•Concomitant Rifampicin
•Concomitant St. John's Wort (Hypericum perforatum)
•Warfarin is allowed; however, close monitoring of Prothrombin Time (PT) is recommended
•Decompensated heart failure (ejection fraction <45%), myocardial infarction or revascularization procedure during the last 6 months, unstable angina pectoris, uncontrolled cardiac arrhythmia
•Hypertension that cannot be controlled by medications (>160/100 mmHg despite optimal medical therapy)
•Patients with recent or active bleeding diathesis
•Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment.
•Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and three months after the completion of trial
•Previous treatment with Sorafenib or other anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study entry
•Radiotherapy during study or within 3 weeks of start of study drug. (Palliative radiotherapy will be allowed).
•Major surgery within 4 weeks of start of study
•Autologous bone marrow transplant or stem cell rescue within 4 months of study
•Use of biologic response modifiers, such as G-CSF, within 3 week of study entry. [G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated or at the discretion of the investigator, however they may not be substituted for a required dose reduction.] [Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or during the study]
•Current treatment with another investigational drug
•Any other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Exclusion Criteria

Not provided

Arms & Interventions

1 arm only

Experimental

One arm only with Sorafenib plus Paclitaxel Patients enrolled will undergo strict follow-up

Intervention: Sorafenib plus Paclitaxel

Intervention: Sorafenib (Drug)

1 arm only

Experimental

One arm only with Sorafenib plus Paclitaxel Patients enrolled will undergo strict follow-up

Intervention: Sorafenib plus Paclitaxel

Intervention: Paclitaxel (Drug)

Outcomes

Primary Outcomes

Disease free survival

Time Frame: 4 months

Secondary Outcomes

Overall survival(4 months)

Investigators

Sponsor

University of Turin, Italy

Sponsor Class

Other

Study Sites (5)

Loading locations...

Similar Trials

Active, not recruiting

Not Applicable

Sorafenib plus paclitaxel metronomic chemotherapy in adreno-cortical-carcinoma patients progressing after 1st or snd line cytotoxic chemotherapy - PAXOACCMedDRA version: 9.1Level: SOCClassification code 10014698Term: Endocrine disordersMedDRA version: 9.1Level: LLTClassification code 10001326Term: Adrenal carcinoma

EUCTR2008-000759-91-ITAZIENDA OSPEDALIERA S. LUIGI GONZAGA25

Recruiting

Phase 2

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell CarcinomaEsophageal Cancer

NCT06718205The First Affiliated Hospital of Zhengzhou University112

Completed

Phase 2

A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).Carcinoma, Hepatocellular

NCT00855218Bayer307

Completed

Phase 2

Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine TumorsNeuroendocrine Tumors

NCT00605566University Health Network, Toronto22

Active, not recruiting

Phase 2

NCT00494182M.D. Anderson Cancer Center48